WAT · CIK 1000697
What Waters Corporation told the SEC could break it.
Waters' register is shaped by what it sells, to whom, and across which borders. No single customer is even 2% of sales, but about 59% of 2025 revenue comes from the pharmaceutical industry, so pharma capital-spending and regulatory cycles drive its results. The rest is geographic and trade exposure: roughly 69% of sales are outside the U.S. — with China demand volatile and most of its instruments built in Ireland, the U.K. and Singapore — leaving it exposed to 2025 U.S. tariffs and China's retaliatory tariffs and export restrictions on certain manufacturing components, on top of a reliance on limited- or single-source suppliers for some specialized parts.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- pharmaceutical end-market (~59% of sales)medium
No single customer is more than 2% of sales, but Waters is concentrated in the pharmaceutical end-market — ~59% of 2025 net sales — so pharma capital-spending and regulatory cycles drive results.
“The Company sells its products and services to a significant number of large and small customers throughout the world, with net sales to the pharmaceutical industry of approximately 59 %, 58 % and 57 % in 2025, 2024 and 2023, respectively. None of the Company's individual customers accounted for more than 2 % of annual Company sales in 2025, 2024 or 2023.”
SEC filing →As of 2026
Geographic concentration
- China demand sensitivity and Ireland/UK/Singapore manufacturingmedium
~69% of sales are outside the U.S.; China demand is volatile (instrument sales fell 15% and overall China sales 10% in 2024 on regulations/macro), and Waters concentrates HPLC/UPLC/MS manufacturing in Ireland, the UK and Singapore.
“In addition, the Company has considerable manufacturing operations in Ireland and the U.K., as well as key subcontractors providing manufacturing and support that are located in Singapore. As a result, a significant portion of the Company's sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment”
Regulatory & policy
- U.S. tariffs (10% baseline) and China retaliation/export restrictionsmedium
2025 U.S. tariffs (10% baseline on imports, plus exceptions) prompted retaliatory tariffs and China export restrictions on certain manufacturing components, raising cost/supply risk for Waters' US/Ireland/UK/Singapore manufacturing network.
“In 2025, the U.S. government issued varying levels of tariffs on all imported goods into the U.S., including a baseline 10% tariff, subject to certain exceptions, which have also prompted retaliatory tariffs by a number of countries, including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries.”
Sole-source dependency
- limited/single-source specialized componentsmedium
While most raw materials are multi-sourced, a number of specialized items are bought from limited or single sources of supply, and supplier consolidation could create additional sole-source dependencies.
“Most of the raw materials, components and supplies purchased by the Company are available from several suppliers; however, a number of items including specialized products are purchased from limited or single sources of supply. Consolidation among such suppliers could also result in other limited or sole-source suppliers for the Company in the future.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch